Drug Trial Radar · NCT03312634
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Last checked: Nov 20, 2026Latest source record: Nov 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Nov 30, 2017
Primary completion
Jan 24, 2020
Study completion Sep 7, 2022
Sponsor
- Lead sponsor
- Clementia Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability.
Conditions
- Fibrodysplasia Ossificans Progressiva
Interventions
PalovaroteneDrug
Palovarotene was taken orally once daily at approximately the same time each day following a meal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized New Heterotopic Ossification (HO)Time frame: Baseline (within one month of screening/Day 1) and up to 24 months
Locations
16 sites in 11 countries. Site status is shown where the registry gives one.
University of California San Francisco, Division of Endocrinology and Metabolism
San Francisco, California
Mayo Clinic
Rochester, Minnesota
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pennsylvania, Internal Medicine
Philadelphia, Pennsylvania
Hospital Italiano de Buenos Aires, Tte General Juan Domingo Peron 4190
Buenos Aires, Argentina
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Queensland University of Technology
Woolloongabba, Queensland, Australia
Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil
Hospital for Sick Children, 555 University Avenue
Toronto, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Groupe Hospitalier Necker Enfants Malades
Paris, France
Istituto Giannina Gaslini
Genoa, Liguria, Italy
The University of Tokyo Hospital
Tokyo, Bunkyo-ku, Japan
Hospital Universitari i Politècnic La Fe, Unidad de Reumatología Pediatrica
Valencia, Avinguda de Fernando Abril Martorell, Nº 106, Spain
Norrlands Universitetssjukhus
Umeå, Sweden
Royal National Orthopaedic Hospital, Brockely Hill
Stanmore, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.